Please login to the form below

Not currently logged in
Email:
Password:

SCCHN

This page shows the latest SCCHN news and features for those working in and with pharma, biotech and healthcare.

Bad news for Innate Pharma as BMS-backed drug stumbles

Bad news for Innate Pharma as BMS-backed drug stumbles

Bad news for Innate Pharma as BMS-backed drug stumbles. Lirilumab combination fails to show additional benefit in SCCHN patients. ... additional benefit compared to Opdivo alone in patients with squamous cell carcinoma of the head and neck (SCCHN).

Latest news

More from news
Approximately 6 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics